FLT3 and acute myeloid leukemia: This result is consistent with that previously published by Sakaguchi et al. [26], where the prognosis was unfavorable in NPM1-mut-positive AML cases with low FLT3–ITD AR when allo-HSCT was not carried out in CR1.